Clinical Trial Update: Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial (COIS-01) examines tislelizumab with dasatinib and quercetin for resectable head and neck squamous cell carcinoma; the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• DASATINIB (Dasatinib)
• Quercetin (quercetin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Head and Neck Squamous Cell Carcinomas | Phase 2 | Status: ACTIVE_NOT_RECRUITING